Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Caplacizumab - Ablynx

Next Previous
Drug Profile

Caplacizumab - Ablynx

Alternative Names: ALX-0081; ALX-0681; Anti-von Willebrand factor Nanobody® - Ablynx; Cablivi; caplacizumab-yhdp

Latest Information Update: 06 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ablynx
  • Developer Ablynx; Sanofi
  • Class Anticoagulants; Antithrombotics; Monoclonal antibodies; Proteins; Recombinant proteins; Single-domain antibodies
  • Mechanism of Action Platelet aggregation inhibitors; Von Willebrand factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Thrombotic thrombocytopenic purpura
  • Discontinued Thrombosis

Most Recent Events

  • 26 Dec 2024 Sanofi completes a phase III trial in Thrombotic Thrombocytopenic Purpura (Adjunctive treatment) in Germany, France, Netherlands, Spain, Czech Republic, USA, Austria, Belgium, Canada, Italy, Japan, United Kingdom (Injection) (NCT05468320) (EudraCT2022-001177-31)
  • 21 Nov 2022 Phase-III clinical trials in Thrombotic thrombocytopenic purpura (Adjunctive treatment) in United Kingdom (IV) (NCT05468320)
  • 28 Oct 2022 Registered for Thrombotic thrombocytopenic purpura in Japan (SC) prior to October 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top